This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Desnick, R. J. Articles by Moller, J. H. Search for Related Content PubMed PubMed Citation Articles by Desnick, R. J. Articles by Moller, J. H.

Circulation, Vol 54, 818-825, Copyright © 1976 by American Heart Association

ARTICLES

Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies

RJ Desnick, LC Blieden, HL Sharp, PJ Hofschire and JH Moller

The cardiovascular abnormalities were investigated in two unrelated hemizygous males with Fabry disease who had clinical mitral insufficiency. Postmortem examination of their hearts revelaed anatomic, ultrastructural and biochemical abnormalities resulting from defective activity of the lysosomal enzyme, alpha-galactosidase A. The ultrastructural and biochemical studies demonstrated the marked accumulation of the major glycosphingolipd substrate, trihexosyl ceramide, in the lyosomes of all the cardiac tissues examined; the greatest concentrations were found in the mitral valve and elft ventricular myocardium. Intriguingly, digalactosyl ceramide, a glycosphingolipid substrate not detectable in normal lung, vessel or cardiac tissues, was found increased only in the lung and right heart tissues. Morphologic and chemical examination of cardiac and systemic vessels demonstrated accumulation of trihexosyl ceramide in lysosomes of the vascular endothelium. These studies demonstrate that the progressive accumulation of trihexosyl ceramide in the lysosomes of the cardiac structures and vascular system leads to the multiple cardiovascular manfiestation of Fabry disease.

This article has been cited by other articles:

				F. Barbey, S. D. Qanadli, C. Juli, N. Brakch, T. Palacek, E. Rizzo, X. Jeanrenaud, B. Eckhardt, and A. Linhart Aortic remodelling in Fabry disease Eur. Heart J., October 21, 2009; (2009) ehp426v1. [Abstract] [Full Text] [PDF]

				A. Linhart, C. Kampmann, J. L. Zamorano, G. Sunder-Plassmann, M. Beck, A. Mehta, P. M. Elliott, and on behalf of European FOS Investigators Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey Eur. Heart J., May 5, 2007; (2007) ehm153v1. [Abstract] [Full Text] [PDF]

				F. Weidemann, F. Breunig, M. Beer, J. Sandstede, S. Stork, W. Voelker, G. Ertl, A. Knoll, C. Wanner, and J. M. Strotmann The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease Eur. Heart J., June 2, 2005; 26(12): 1221 - 1227. [Abstract] [Full Text] [PDF]

				P. Kotanko, R. Kramar, D. Devrnja, E. Paschke, T. Voigtlander, M. Auinger, K. Demmelbauer, M. Lorenz, A.-C. Hauser, H.-J. Kofler, et al. Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1323 - 1329. [Abstract] [Full Text] [PDF]

				E. Gilbert-Barness Metabolic Cardiomyopathy and Conduction System Defects in Children Ann. Clin. Lab. Sci., January 1, 2004; 34(1): 15 - 34. [Abstract] [Full Text] [PDF]

				S F Nagueh Fabry disease Heart, August 1, 2003; 89(8): 819 - 820. [Full Text] [PDF]

				C. Kampmann, F. Baehner, C. Whybra, C. Martin, C. M. Wiethoff, M. Ries, A. Gal, and M. Beck Cardiac manifestations of Anderson-Fabry disease in heterozygous females J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1668 - 1674. [Abstract] [Full Text] [PDF]

				C. Kampmann, F. Baehner, M. Ries, and M. Beck Cardiac Involvement in Anderson-Fabry Disease J. Am. Soc. Nephrol., June 1, 2002; 13(90002): S147 - 149. [Full Text] [PDF]

				P. Boutouyrie, S. Laurent, B. Laloux, O. Lidove, J.-P. Grunfeld, and D. P Germain Non-invasive evaluation of arterial involvement in patients affected with Fabry disease J. Med. Genet., September 1, 2001; 38(9): 629 - 631. [Full Text] [PDF]

				R. Schiffmann, J. B. Kopp, H. A. Austin III, S. Sabnis, D. F. Moore, T. Weibel, J. E. Balow, and R. O. Brady Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial JAMA, June 6, 2001; 285(21): 2743 - 2749. [Abstract] [Full Text] [PDF]

				S. Nakao, T. Takenaka, M. Maeda, C. Kodama, A. Tanaka, M. Tahara, A. Yoshida, M. Kuriyama, H. Hayashibe, H. Sakuraba, et al. An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy N. Engl. J. Med., August 3, 1995; 333(5): 288 - 293. [Abstract] [Full Text] [PDF]

				E. A. Fisher, R. J. Desnick, R. E. Gordon, C. M. Eng, R. Griepp, and M. E. Goldman Fabry Disease: An Unusual Cause of Severe Coronary Disease in a Young Man Ann Intern Med, August 1, 1992; 117(3): 221 - 223. [Abstract] [PDF]

				N. A. Sher, W. Reiff, R. D. Letson, and R. J. Desnick Central Retinal Artery Occlusion Complicating Fabry's Disease Arch Ophthalmol, May 1, 1978; 96(5): 815 - 817. [Abstract] [PDF]